 
STU022017 -075, Parsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)    
  
CONFIDENTIAL  
This material is the property of the UTSW Simmons Comprehensive Cancer Center .  
Do not disclose or use except as authorized in writing by [CONTACT_4530].  
 Template Updated: 12/2012 ; 9/2013; 8/2014; 4/2015; 10/2015; 11/2016; 12/2018; 07/2020  
 
STU 022017 -075 
VisionRT -based Deep Inspi[INVESTIGATOR_360857] -hold (DIBH) Respi[INVESTIGATOR_360858], A Pi[INVESTIGATOR_360859] :  David Parsons , Ph.D.  
UT Southwestern Medical Center  
[ADDRESS_449938], Dallas, TX, [ZIP_CODE]  
Phone: (214)648 -9941  
Fax: (214) -648-8051  
[EMAIL_6913]  
                                               
                                                Robert Timmerman, M.D.  
UT Southwestern Medical Center  
[ADDRESS_449939], Dallas, TX, [ZIP_CODE]  
Phone: (214)645 -7637  
Fax: (214) -645-8526  
[EMAIL_6914]  
 
 
     
Biostatistician :   Department of Clinical Sciences  
    Chul Ahn, Ph.D.  
UT Southwestern Medical Center  
[ADDRESS_449940], Dallas, TX, [ZIP_CODE]  
(214)648 -9418  
[EMAIL_6915]  
     
 
Funding Source :  Supported by [CONTACT_360887] (London, [LOCATION_008])  
 
 
 
Initial version:   
Version  Date  
Initial  3/20/2017  
Version 2  07/16 /2019  
Version 3  10/26/2020  
Version 4  04/19/2021  
 
 
 
 
UT Southwestern Medical Center  (UTSW)  
Harold C. Simmons Comprehensive Cancer Center  
Attn: Clinical Research Office  
[ADDRESS_449941]. MC 9179  
 
STU022017 -075, Parsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)    
  
CONFIDENTIAL  
This material is the property of the UTSW Simmons Comprehensive Cancer Center .  
Do not disclose or use except as authorized in writing by [CONTACT_4530].  
 Template Updated: 12/2012 ; 9/2013; 8/2014; 4/2015; 10/2015; 11/2016; 12/2018; 07/2020  
 
Dallas, [LOCATION_007] [ZIP_CODE] -9179   
 
STU022017 -075, Parsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)    
  
CONFIDENTIAL  
This material is the property of the UTSW Simmons Comprehensive Cancer Center .  
Do not disclose or use except as authorized in writing by [CONTACT_4530].  
 Template Updated: 12/2012 ; 9/2013; 8/2014; 4/2015; 10/2015; 11/2016; 12/2018; 07/2020  
 
 
Signature [CONTACT_264032], and provides the necessary 
assurances that this trial will be conducted according to all stipulations of the protocol, including all statements 
regarding confidential ity, and according to local legal and regulatory requirements and applicable U.S. federal 
regulations and ICH guidelines.  
 
Version # 4 
STU 022017 -075 
VisionRT -based Deep Inspi[INVESTIGATOR_360857] -hold (DIBH) Respi[INVESTIGATOR_360860], A Pi[INVESTIGATOR_360861] (PI) Name :_____________________________  
 
 
 
PI [INVESTIGATOR_7496]: __________ __________ _________  
 
 
 
Date:____________________  
 
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, Parsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
i TABLE OF CONTENTS  
LIST OF ABBREVIATIONS (EXAMPLES)  ................................ ................................ .1 
STUDY SCHEMA  ................................ ................................ ................................ ............. 2 
................................ ................................ ................................ ................................ .............. 2 
................................ ................................ ................................ ................................ .............. 3 
................................ ................................ ................................ ................................ .............. 3 
................................ ................................ ................................ ................................ .............. 3 
STUDY SUMMARY  ................................ ................................ ................................ .......... 4 
1.0 BACKGROUND AND R ATIONALE  ................................ ................................ ..5 
1.1 Background  ................................ ................................ ................................ ......................  5 
1.2 DIBH and Active Breathing Coordinator (ABC)  ................................ ...............................  5 
1.3 VRT and VRT -DIBH ................................ ................................ ................................ .........  6 
2.0 STUDY OBJECTIVES  ................................ ................................ ........................... 6 
2.1 Primary Objectives  ................................ ................................ ................................ ...........  7 
2.2 Secondary Objectives  ................................ ................................ ................................ ...... 7 
2.3 Exploratory Objectives  ................................ ................................ ................................ ..... 7 
2.4 Endpoints  ................................ ................................ ................................ .........................  7 
3.0 PATIENT ELIGIBILITY  ................................ ................................ ...................... 7 
3.1 Inclusion Criteria  ................................ ................................ ................................ ..............  7 
3.2 Exclusion Criteria  ................................ ................................ ................................ .............  8 
4.0 TREATMENT PLAN  ................................ ................................ ............................. 8 
4.1 Treatment Dosage and Administration  ................................ ................................ ............  8 
4.2 Concomitant Medications/Treatments  ................................ ................................ .............  9 
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, Parsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
ii 4.[ADDRESS_449942] Replacement ................................ ................................ ................................ ..... 10 
5.0 STUDY PROCEDURES  ................................ ................................ ...................... 10 
5.1 Screening/Baseline Procedures  ................................ ................................ ....................  10 
5.2 Procedures during Treatment  ................................ ................................ ........................  11 
5.3 Follow -up procedures  ................................ ................................ ................................ .... 12 
5.4 Time and Events Table  ................................ ................................ ................................ .. 13 
5.5 Removal of Subjects from Study  ................................ ................................ ...................  13 
6.0 STATISTICAL CONSIDERATIONS  ................................ ................................ 13 
6.1 Study Design/Study Endpoints  ................................ ................................ ......................  [ADDRESS_449943] (IRB) Approval and Consent  ................................ ...............  19 
8.3 Registration Procedures  ................................ ................................ ................................  19 
8.4 Data Management and Monitoring/Auditing  ................................ ................................ .. 20 
8.5 Adherence to the Protocol  ................................ ................................ .............................  20 
8.6 Amendments to the Protocol  ................................ ................................ .........................  21 
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, Parsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
iii 8.[ADDRESS_449944] Retention  ................................ ................................ ................................ ...........  22 
8.8 Obligations of Investigators  ................................ ................................ ...........................  22 
9.0 REFERENCES  ................................ ................................ ................................ ......22 
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
[ADDRESS_449945] OF ABBREVIATIONS  (EXAMPLES)  
AE Adverse Event  
ABC                    Active Breathing Coordinator  
ALC  
ASCO  Absolute Lymphocyte Count  
American Society of Clinical Oncology  
BH Breath Hold  
CR Complete Response  
CT Computed Tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
DLT  Dose Limiting Toxicity  
DOT  Disease Oriented Team  
DSMB  Data and Safety Monitoring Board  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
H&P  History & Physical Exam  
HRPP  Human Research Protections Program  
IHC Immunohistochemistry  
IND Investigational New Drug  
IV (or iv)  Intravenously  
MRI  Magnetic Resonance Imaging  
MTD  Maximum Tolerated Dose  
MV Mega Voltage  
NCI National Cancer Institute  
ORR  Overall Response Rate  
OS Overall Survival  
pCR Pathologic Complete Response  
PD Progressive Disease  
PET Positron Emission Tomography  
PFS Progression Free Survival  
p.o. peros/by [CONTACT_1966]/orally  
PR Partial Response  
RCB  Residual Cancer Burden  
RECIST  Response Evaluation Criteria in  Solid Tumors  
SAE  Serious Adverse Event  
SCCC  Simmons Comprehensive Cancer Center  
SD Stable Disease  
SOC  Standard of Care  
VRT  Vision RT  
VRT -DIBH  VRT -assisted DIBH  
 
 
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
2 STUDY SCHE MA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Thoracic and abdominal cancer  patients eligible for SBRT treatment  
Pre-oxygenation VRT -DIBH patient training and find a patient -specific optimal 
deep inspi [INVESTIGATOR_317967] (DIBH) level  assisted with a Spi[INVESTIGATOR_360862] > 5mm  
(SOC evaluated with imaging ) 
Yes No 
A single DIBH duration >= 30 
seconds  
Yes No 
VRT Real -time coaching coupled with DIBH (VRT -DIBH) training  
 
Inter - & Intra -VRT -DIBH surface 
variation < = 5mm No 
 Intra-VRT -DIBH tumor motion 
<=5mm(evaluated with imaging)  Yes Yes 
No Consent  
Yes Not eligible for the study,  
Not eligible for the study. 
Use other SOC for 
motion control  
Inter - VRT -DIBH patient tumor position & surface stability/repeatability study with CT images:  
• SOC high -resolution CT image s acquisition within  DIBH  
• Repeat a low -resolution/low -dose CT image acquisition in another DIBH within 10mins 
interval  
• Acquire two low -resolution CT at ±10% DIBH levels   Inter-VRT -DIBH tumor motion 
<=5mm(evaluated with imaging)  No 
Yes Off study. Data 
collection only, use other 
SOC for  motion control  
Off study. Data 
collection only, use other 
SOC for  motion control  
Off study/ Data 
collection only, use other 
SOC for  motion control  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Treatment planning wi th the acquired SOC CTs  
VRT -SBRT treatment setup  
• Spi[INVESTIGATOR_14007] – setup with tidal volume  
• VRT – surface alignment  
• CBCT – target alignment  
VRT -SBRT treatment delivery monitoring/recording  per SOC (unless otherwise noted)  
• Spi[INVESTIGATOR_14007]  –  Tidal volume stability/reproducibility  
• VRT  – Surface stability/reproducibility -Research  
• kV fluoro  – in any two VRT -DIBH durations to evaluate tumor position accuracy   
• Intra -fraction CBCT  – one CBCT before the first beam delivery and one CBCT before 
the last  beam  delivery  (not during arc delivery)  
Data a nalysis  
• Treatment time  
• Inter/intra VRT -DIBH patient surface stability/reproducibility  
• Inter/intra VRT -DIBH  tumor position accuracy/stability/reproducibility  
• Inter VRT -DIBH surface/tumor position correlation  
• VRT -DIBH  SBRT planned/delivered dose variation  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
4 STUDY SUMMARY  
Title  VisionRT -based Deep Inspi[INVESTIGATOR_360857] -hold (DIBH) Respi[INVESTIGATOR_360863], A Pi[INVESTIGATOR_360864] -DIBH for Thoracic and Abdominal Cancer SBRT  
Protocol Number  STU 022017 -075 
Phase  Pi[INVESTIGATOR_360865]  2 year  
Study Center(s)  Single -center  
Objectives  To prove the feasibility of  using VRT -DIBH  for thoracic and 
abdominal tumors SBRT  
Number of Subjects  10 
Diagnosis and Main 
Inclusion Criteria  • Patients with tumors in thorax and abdomen  
• Patients are eligible for SBRT  
Study Product(s), Dose, 
Route, Regimen  No therapeutic intervention – per SOC  
Duration of 
administration  Per SOC  
Statistical Methodology  Descriptive statistics will be computed to investigate the feasibility 
of the trial.  
 
 
 
 
 
  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
[ADDRESS_449946] 
prevalence and relevance for motion -management needed radiotherapy are lung and liver 
cancer.  Lung cancer is the leading cause of cancer -related mortality in the [LOCATION_002].  
During 2016, an  estimated 224,390 new cases of lung cancer are diagnosed, representing 
13% of all cancer patients1, and an estimated 158,080 deaths of lung cancer were expected1. 
The five -year surviv al rate for all stages combined is 17.7%, lower than many other leading 
cancer sites, such as the colon (64.4%), breast (89.7%) and prostate (98.9%)2. Liver cancer 
is the 10th most common cancer. In 2016, an estimated 39,230 adults (28,410 men and 
10,820 women) in the [LOCATION_002] will be diagnosed with primary liver cancer1. The 5 -
year survival rate of liver cancer is 17%2. 
 
Stereotactic body radiotherapy (SBRT) is a therapeutic paradigm developed in the mid 
1990’s. It administers very high, biological p otent doses in few fractions (1 - 5 fractions) 
using unique beam arrangements and special immobilization equipment. It has 
demonstrated excellent local control in patients with inoperable non -small cell lung cancer 
(NSCLC)[ADDRESS_449947] been explored and implemented for clinical use, including motion -
encompassing methods [e.g. 4D CT and ITV (internal target volume) app roach], abdominal 
compression techniques to decrease motion amplitude, breath -holding methods, 
respi[INVESTIGATOR_696] -gating techniques, and real -time tumor -tracking methods. All of these 
techniques aim to mitigate dosimetric uncertainties induced by [CONTACT_15206][INVESTIGATOR_360866].  
1.2 DIBH and Active Breathing Coordinator ( ABC)  
Among various respi[INVESTIGATOR_360867], deep -inspi[INVESTIGATOR_212746] -hold 
(DIBH) technique has been developed and applied in lung and liver SBRT.11, [ADDRESS_449948] is by 
[CONTACT_2329] a commercially available system Active Breathing Coordinator (ABC; Elekta, 
Crawley, [LOCATION_006]) device. The ABC system has a digital spi[INVESTIGATOR_360868]. When the patient inspi[INVESTIGATOR_36736] a preset DIBH level, a balloon  valve is inflated so 
as to prevent the patient from breathing out and thereby [CONTACT_360888] a consistent chest wall 
expansion with each DIBH. A nose clip prevents air leakage. The therapi[INVESTIGATOR_360869] 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
[ADDRESS_449949] conventional irradiation are used ABC assisted DIBH (ABC -DIBH) for 
respi[INVESTIGATOR_120985].  
 
Several studies have pointed out potential drawbacks of the ABC system. For example, 
even though the patient’s tidal volume remains consistent with ABC, different breathing 
maneuvers (abdominal versus thoracic breathing) can cause for variations in breath -hold.[ADDRESS_449950] wall expansion of  1.9 cm. Remouchamps et al.  also showed 
that that overshoot can occur with ABC device where the patient can inhale a larger air 
volume than the pre -determined set limit.13, 16 More recently, Mittauer et al.  showed 
through using an optical surface -tracking system to monitor ABC -assisted DIBH, that large 
positional variations can occur in some patients due to their different breath hold 
techniques17 and concluded that optical tracking system is a valuable tool for ABC -assisted 
DIBH.  
1.3 VRT and VRT -DIBH  
A more recent competing technology for implementing the DIBH technique is real -time 
surface photogrammetry using the AlignRT sy stem (Vision RT Ltd., London, [LOCATION_006]). 
AlignRT system use non -ionization near infrared light to track patient surface motion. The 
system has one projector projecting near infrared optical pattern on patient surface. The 
optical pattern is imaged by [CONTACT_360889] (two per pod) at ~[ADDRESS_449951] (ROI) on the surface and the software calculates and displays the real -
time position in six degrees (3 translations and 3 rotations) in real -time. Once the patient 
has matched the pre -determined DIBH position (within threshold accuracy), the radiation 
beam is enabled to be turned on for treatment.  
 
Currently, VRT -DIBH has already applied to left breast radiotherapy to spare lung and 
heart. Compared to ABC -DIBH, VRT -DIBH has several potentia l advantages:  
1. VRT monitors patient (surface) position in addition to DIBH signal,  while ABC only 
check the tidal volume, which can remain the same even if the patient shifts slightly on 
the couch;  
2. VRT is more cost effective, as patient tubing needs to be replaced daily for ABC;  
3. VRT potentially has advantage on patient compliance, as with ABC breath is forced 
impeded while with VRT breath -hold is voluntary.   
 
In this study, we renovate the established DIBH motion management strategy by [CONTACT_360890]. The purpose of this study is to develop, validate, and prove the feasibility 
of VRT -DIBH technique for lung and liver SBRT.  
 
2.0 STUDY OBJECTIVES  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
7 2.1 Primary Objectives  
2.1.1  To investigate the feasibility of applying VRT -DIBH to lung/liver cancer 
SBRT  
2.2 Secondary Objectives  
2.2.1  To determine planning target volume margin by [CONTACT_360891] -DIBH  
2.2.2  To determine VRT surface monitoring threshold by [CONTACT_360892]/intra 
VRT -DIBH patient surface stability/reproducibility/se nsitivity  
2.3 Exploratory Objectives  
2.3.1  To quantify SBRT dose variation between planned and delivered with VRT -
DIBH technique.  
2.3.2 Treatment time  
2.4 Endpoints  
2.4.1  VRT -DIBH feasibility  
2.4.2  To determine target margin in VRT -DIBH lung/liver SBRT  
2.4.3   To determine threshold used for surface monitoring in VRT -DIBH assisted 
lung/liver SBRT  
   
3.[ADDRESS_449952] 30 seconds – later to be confirmed.  
3.1.[ADDRESS_449953] agree to use adequate 
contraception (hormonal or barrier method of birth control; abstinence) prior to study 
entry, and until study  imaging  is complete . Should a woman become pregnant or 
suspect she is pregnant while participating in this study, she should inform her 
treating physician immediately.  
 
[IP_ADDRESS]  A female of child -bearing potential is any woman ( regardless of sexual 
orientation, marital status, having undergone a tubal ligation, or 
remaining celibate by [CONTACT_75121]) who meets the following criteria:  
 
 Has not undergone a hysterectomy or bilateral oophorectomy; or  
 Has not been naturally postmenopausal fo r at least 12 consecutive 
months (i.e., has had menses at any time in the preceding 12 
consecutive months).  
 
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
[ADDRESS_449954] be compliant to all required pretreatment evaluations (section 
5.1) 
3.2 Exclusion Criteria  
3.2.1 Pregnant or lactating women, as treatment invo lves unforeseeable risks to 
the embryo or fetus  
3.2.2 Patients are  not compliant to all required pretreatment evaluations (section 
5.1). 
 
4.0 TREATMENT PLAN  
4.1 Treatment Dosage and Administration  
Patient recruit on this treatment protocol will go through training -screening 
sessions:  
1. Patient will go through a tumor motion evaluation session. Since we would like 
to test the effectiveness of our proposed motion management strategy, we 
would like to recruit patient with tumor motion in one direction is larger than 5 
mm.  Tumor motion in free -breathing mode will be evaluated under imaging 
study. . 
2. Patient will go through a pre -oxygenation training -screening session. Research 
studies18, 19 already  shown that pre-oxygenation can effectively prolong  breath -
holds  in patients  with cancer . In this study we will combine patient training, 
screening, and pre -oxygenation to prolong patient breath -hold duration in 
radiotherapy procedure. Patient will be aske d to breathing oxygen -enhanced air 
through a facial mask and take deep inspi[INVESTIGATOR_317967]. We will use 
spi[INVESTIGATOR_360870] a 
comfortable/optimal breath hold level ~75% of the maximum deep inspi[INVESTIGATOR_1516].  
Only patient can have single DIBH duration > = [ADDRESS_449955]/abdomen surface. During the surface  image acquisition, imaging will be 
used to acquire tumor position or diaphragm position. The surface images and 
tumor positions acquired in single DIBH durations will be used to quantify 
intra-DIBH patient surface and tumor position stability. The surface  images and 
tumor positions acquired across several DIBH durations will be used to quantify 
inter-DIBH patient surface and tumor position repeatability. The intermittent 
time between DIBH durations can be varied between 1 -10 minutes.  
4. Only patient with inte r/intra -DIBH tumor position variation < =5 mm and 
inter/intra -DIBH surface level variation < = [ADDRESS_449956] of care.  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
[ADDRESS_449957] will be acquired in 
single DIBH duration. Within 10 minute, a low -resolution/low -dose CT 
image in single DIBH duration will be acquired. This study is to quantify 
inter-DIBH tumor position and patient surface repea tability.  
2. Patient will then be scanned using a low er dose CT protocol with DIBH 
level set at ±10% deviated from the selected DIBH level. This study is to 
find the correlation between DIBH level and tumor position /chest -abdomen 
surface level.  
 
The SOC DI BH CT scan will be transferred to Eclipse treatment planning system 
for treatment planning. Tidal volume measured by [CONTACT_15209][INVESTIGATOR_360871] a reference surface for patient treatment initial setup. 
CBCT will be acquired be fore each fractional treatment for the patient alignment 
before beam delivery.  
 
During the treatment delivery, patient will perform DIBH while AlignRT system 
monitors patient surface. As a pi[INVESTIGATOR_799], we will also use spi[INVESTIGATOR_360872] -hold tidal volume, and imaging acquired in any two DIBH periods 
to quantify inter - and intra - DIBH tumor position variation. Following our SBRT 
treatment protocol, patient will get CBCT scan before the last beam delivery. We 
will follow the same protocol to acquire CBCT images. These CBCT images will 
be used to evaluate treatment dose variation to quantify treatment delivery 
accuracy.  
  
4.2 Concomitant Medications/Treatments  
Concomitant medications allowable as deemed appropriate by [CONTACT_44375].  
4.[ADDRESS_449958] day of radiation. Other exceptions may 
apply:  
 Disease progression  
 Inter -current illness that prevents further administration of treatment  
 Unacceptable adverse event(s)  
 Subject  decides to withdraw from the study, OR 
 General or specific changes in the patient’s condition render the subject 
unacceptable for further treatment in the judgment of the investigator”.  
4.4 Duration of Follow Up  
No follow -up required for this study af ter radiation completed.  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
[ADDRESS_449959] was removed in the Case Report Form.  
5.0 STUDY PROCEDURES  
5.1 Screening/Baseline Procedures  
Assessments performed exclusively to determine eligibility for this study will be 
done only after obtaining informed consent. Assessments performed for clinical 
indications (not exclusively to determine study eligibility) may be used for baseline 
values even if the studies were done before in formed consent was obtained.  
 
All screening procedures must be performed within  60 days prior to registration 
unless otherwise stated. The screening procedures include:  
5.1.[ADDRESS_449960] eligibility criteria  
5.1.5  Physical exam including vital signs, height and weight  
Vital signs (temperature, pulse, respi[INVESTIGATOR_1520], blood pressure) for each 
protocol related visit.  
5.1.[ADDRESS_449961] (for females of child bearing potential)  
See section  3.1.[ADDRESS_449962] they are not pregnant.  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
11 5.1.8  Breathing evaluation  
Treatment target motion, surface motion and breathing duration will be 
evaluated before SBRT  (does not have to be don e prior to registration) . The 
following screening procedures will be pursued sequentially:  
1. Free-breathing tumor motion evaluation: imaging  will be acquired and 
physician will determine whether tumor motion > 5 mm.  
2. For those patients with tumor motion > [ADDRESS_449963] breath -holding time. If patients can hold 
breath > = [ADDRESS_449964] DIBH and optical cameras will monitor patient 
surface during breath hold. If surface motion > [ADDRESS_449965] setting within 5 mm tolerance, 
patient will move on for the further study step.  
4. DIBH tumor motion evaluation: after surface motion evaluation, DIBH 
tumor motion evaluation will be conducted under imaging  one more 
time. Imaging  will be acquired and physician will determine whether 
tumor motion < = [ADDRESS_449966] simulation  
 CT Simulation scans at DIBH will be assisted by [CONTACT_15209][INVESTIGATOR_14007] ---must 
ensure tubing fr om spi[INVESTIGATOR_360873].  
 CT simulation scan (full -length) will be acquired with at a single DIBH 
duration, starting at least [ADDRESS_449967] administration.  
 CT acquisition should be done wi th gantry 0 degree with spacing ≤ 2 
mm.  
 Additional  DIBH CT scans will be conducted using low er dose CT scan 
protocol. One at the same DIBH level and the other two will be ±10% 
deviated from DIBH breath level  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
12  All images will be transferred to the treatment  planning computers for 
tumor motion evaluation and planning.  
5.2.2  Tumor motion evaluation and target volume delineation  
On the acquired four different DIBH CTs, gross tumor volume (GTV) will 
be contoured by [CONTACT_360893]. Tumor center poin t 
(center of mass) will be the identified and used for motion evaluation. Both 
inter- and intra - motion amplitude will be analyzed and margins will be 
estimated. The acquired high -resolution DIBH CT will be used as a primary 
image for planning. Physician w ill expand the GTV to PTV by [CONTACT_360894].  
5.2.3  Critical organs delineation  
SOC  
5.2.4  Treatment planning  
SOC  
5.2.5  Daily treatment  
- Patient will be positioned with vac lock bag in stereotactic body frame and 
setup with stereotactic coordinates recorded during simulation;  
- Setup DIBH tidal volume use spi[INVESTIGATOR_360874];  
-  Initial setup patient position with AlignRT system using CT surface;  
-  Patient will receive a CBCT scan and align to simulated CT images;  
- Right after CBC T alignment, AlignRT system will acquire a new surface 
image for treatment monitoring;  
-  Treatment delivery follows routine SBRT treatment, with one CBCT 
check before and one CBCT before last beam  (not during treatment beam 
delivery) . 
 
 5.2.[ADDRESS_449968].  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
[ADDRESS_449969] they are not pregnant  
 C Only vital signs, once per week  
5.5 Removal of Subjects from Study  
Subjects can be taken off the study treatment and/or study at any time at their own 
request, or they may be withdrawn  at the discretion of the investigator for safety, 
behavioral or administrative reasons. The reason(s) for discontinuation will be 
documented and may include:  
5.5.[ADDRESS_449970] voluntarily withdraws from treatment (follow -up permitted);  
5.5.[ADDRESS_449971] withdraws  consent (termination of treatment and follow -up); 
5.5.[ADDRESS_449972] is unable to comply with protocol requirements;  
5.5.[ADDRESS_449973] demonstrates disease progression (unless continued treatment with 
study drug is deemed appropriate at the discretion of the inves tigator);  
5.5.[ADDRESS_449974]’s continuation on the 
protocol  
5.5.6  Treating physician judge’s continuation on the study would not be in the 
subje ct’s best interest;  
5.5.[ADDRESS_449975] becomes pregnant  
5.5.8    Development of second malignancy (except for basal cell carcinoma or 
squamous cell carcinoma of the skin) that requires treatment, which would 
interfere with this study;  
5.5.[ADDRESS_449976] 
lung/liver cancer SBRT, we will recruit 10 patients. A sample size justification was not 
made since this is a pi[INVESTIGATOR_360875]. 
Descriptive statistics will be computed to estimate the sample size needed for a future 
larger trial if the study results look promising. The trial is considered feasible and 
promising if 50% of enrolled patients  can finish breath -holding SBRT.  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
14 6.1 Study Design/Study Endpoints  
A single -center prospective pi[INVESTIGATOR_360876]. Informed consent will be obtained from 
10 thoracic or abdominal cancer patients, each to be treated with SBRT technique. 
In order to quantify tumor motion/surface stability and repeatability during VRT -
DIBH, several CT images will be acquired during treatment simulation, as well as 
CBCT and VRT surface images during tr eatment delivery. The designed study aims 
to explore the geometry and dosimetry accuracy of VRT -DIBH in thoracic or 
abdominal cancer SBRT.  
6.2 Sample Size and Accrual  
As this is a pi[INVESTIGATOR_799], we will recruit 10 patients and use descriptive statistics to 
characterize tumor motion/surface stability & repeatability during VRT -DIBH and 
its dosimetric impact in terms of dose deviation to tumor and critical organs.  
 A sample size justification was not made since this is a pi[INVESTIGATOR_799]. Descriptive 
statistics wil l be computed to estimate the sample size needed for a future larger 
trial if the study results look promising. We anticipate that the proposed trial will 
be completed in [ADDRESS_449977] safety and care.  
 
All subjects experiencing an adverse event, regardless of its relationship to study 
therapy, will be monitored until:  
 the adverse event resolves or the symptoms or signs that constitute the adverse 
event return to baseline or is stable in the opi[INVESTIGATOR_871];  
 there is a satisfactory explanation other than the study therapy for the changes 
observed; or  
 death.  
 
[Inserted from Adverse Event Definitions and Reporting Section – Appendix II of 
the SCCC DSM C Plan]  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
[ADDRESS_449978] or unfavorable medical occurrence in a 
human research study participant, including any abnormal sign (for example, abnormal 
physical exam, imaging finding or clinically significant laboratory finding), symptom, 
clinical event, o r disease, temporally associated with the subject’s participation in the 
research, whether or not it is considered related to the subject’s participation in the 
research.  
Adverse events encompass clinical, physical and psychological harms. Adverse events 
occur most commonly in the context of biomedical research, although on occasion, they 
can occur in the context of social and behavioral research. Adverse events may be 
expected or unexpected.  
Acute Adverse Events  
Adverse events occurring in the time period  from the signing of the informed consent, 
through the last day of treatment  will be considered acute adverse events . 
Severity  
Adverse events will be graded by a numerical score according to the defined NCI 
Common Terminology Criteria for Adverse Events ( NCI CTCAE) Version 5.0. Adverse 
events not specifically defined in the NCI CTCAE will be scored on the Adverse Event log 
according to the general guidelines provided by [CONTACT_114642].   
 Grade 1: Mild  
 Grade 2: Moderate  
 Grade 3: Severe  or medically significant but not immediately life threatening  
 Grade 4: Life threatening consequences  
 Grade 5: Death related to the adverse event  
 
Serious Adverse Events  
OHRP and UTSW HRPP define serious adverse events as those events, occurring at 
any dose, which meets any of the following criteria:  
 results in death;  
 is life -threatening (places the subject at immediate risk of death from the event as 
it occurred);  
 result s in inpatient hospi[INVESTIGATOR_059]1,2 or prolongation of existing hospi[INVESTIGATOR_059];  
 results in a persistent or significant disability/incapacity;  
 results in a congenital anomaly/birth defect; or  
 based upon appropriate medical judgment, may jeopardize the subjec t’s health 
and may require medical or surgical intervention to prevent one of the other 
outcomes listed in this definition.  
  
Note: A “Serious adverse event” is by [CONTACT_283095]. Serious adverse events may or may not be related to the research project. A 
serious adverse event determination does not require the event to be related to the 
research. That is, both events completely unrelated to the condition under study and 
events that are expected in the context of th e condition under study may be serious 
adverse events, independent of relatedness to the study itself. As examples, a car 
accident requiring >24 hour inpatient admission to the hospi[INVESTIGATOR_263996] a serious 
adverse event for any research participant; likewis e, in a study investigating end -stage 
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
16 cancer care, any hospi[INVESTIGATOR_263997] -specified 
period of monitoring for adverse and serious adverse events would be a serious adverse 
event, even if the event observed is a primary  clinical endpoint of the study.  
1Pre-planned hospi[INVESTIGATOR_114579]. Note: If 
events occur during a pre -planned hospi[INVESTIGATOR_64329], that prolong the existing 
hospi[INVESTIGATOR_059], those events should be evaluated  and/or reported as SAEs.   
2 NCI defines hospi[INVESTIGATOR_263999] 24 hours. Hospi[INVESTIGATOR_360877] b e used for situations where the AE 
truly fits this definition and NOT for hospi[INVESTIGATOR_360878]. 
For example: a hospi[INVESTIGATOR_114582] a patient is admitted for observation or minor 
treatment (e.g. hydration) and released in le ss than 24 hours. Furthermore, 
hospi[INVESTIGATOR_264001] a routine AE or in an expedited report.  
7.1.2  Unanticipated Problems Involving Risks to Subjects or Others (UPI[INVESTIGATOR_20865]):  
The phras e “unanticipated problems involving risks to subjects or others” is found, but not 
defined in the HHS regulations at 45 CFR 46, and the FDA regulations at 21 CFR 
56.108(b)(1) and [ADDRESS_449979], which is defined in 21 CFR 812.3(s). Guidance from 
the regulatory agencies considers unanticipated problems to include any incident, 
experience, or outcome that meets ALL three (3) of the following criteria:  
• Unexpected in terms of nature,  severity or frequency given (a) the research procedures 
that are described in the protocol -related documents, such as the IRB -approved research 
protocol and informed consent document; and (b) the characteristics of the subject 
population being studied;  
    AND  
• Related or possibly related to participation in the research (possibly related means there 
is a reasonable possibility that the incident, experience, or outcome may have been 
caused by [CONTACT_3459]);  
 AND  
• Suggests that th e research places subjects or others at greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized. Note: According to OHRP, if the adverse event is serious, it would always 
suggest a greater risk of harm.  
 
Follow -up  
All adverse events will be followed up according to good medical practices.  
  
7.2 Steps to Determine If a Serious Adverse Event Requires Expedited Reporting to the 
SCCC DSMC  
Step 1 : Identify the type of adverse event using the NCI Co mmon Terminology Criteria 
for Adverse Events (CTCAE v5).  
 
Step 2 : Grade the adverse event using the NCI CTCAE v5.  
 
Step 3 : Determine whether the adverse event is related to the protocol therapy.  
Attribution categories are as follows:  
- Definite – The AE is clearly related  to the study treatment.  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
17 - Probable – The AE is likely related to the study treatment.  
- Possible – The AE may be related  to the study treatment.  
- Unlikely – The AE may NOT be  related  to the study treatment.  
- Unrelated – The AE is clearly NOT rel ated to the study treatment.  
Note : This includes all events that occur to the end of the acute adverse events reportin g 
period as defined in section 7.1.1 .  
 
Step 4 : Determine the prior experience of the adverse event. Expected events are those 
that have b een previously identified as resulting from administration of the treatment. An 
adverse event is considered unexpected, for expedited reporting purposes only, when 
either the type of event or the severity of the event is not listed in:  
 the current known ad verse events listed in the Agent Information Section of this 
protocol (if applicable);  
 the drug package insert (if applicable);  
 the current Investigator’s Brochure (if applicable)  
 the Study Agent(s)/Therapy(ies) Background and Associated Known Toxicities 
section of this protocol  
 
7.2.1  Reporting SAEs and UPI[INVESTIGATOR_264002] 
(SCCC) Data Safety Monitoring Committee (DSMC)  
 
SAEs and UPI[INVESTIGATOR_114585], which occur in research subjects on protocols for which 
the SCCC is the DSMC of record require reporting to the DSMC regardless of whether 
IRB reporting is required. All SAEs occurring during the protocol -specified monitoring 
period and all UPI[INVESTIGATOR_360879] 5 business days 
of the study team members a wareness of the event(s). In addition, for participating 
centers other than UTSW, local IRB guidance should be followed for local reporting of 
serious adverse events or unanticipated problems.  
 
The UTSW study PI [INVESTIGATOR_360880]/UPI[INVESTIGATOR_360881]. This may be facilitated by [CONTACT_264023], study team, sub -
site or other designee. Hardcopi[INVESTIGATOR_264006]; FDA Form #3500A forms, or other sponsor forms, if ap plicable; and/or any other 
supporting documentation available should be submitted to the DSMC Coordinator.  The 
DSMC Coordinator forwards the information onto the DSMC Chairman who determines if 
immediate action is required.  Follow -up eIRB reports, and al l subsequent SAE or UPI[INVESTIGATOR_114590]. (See Appendix III of the SCCC DSMC Plan for a template Serious 
Adverse Event Form which may be utilized).  
   
If the event occurs on a multi -institutional clinical trial coordinated by [CONTACT_264024], the IIT Project Manager or designee ensures that all 
participating sites are notified of the event and resulting action, according to FDA 
guidance for expedited reporting. DSMC Chairperson reviews all SAEs and UPI[INVESTIGATOR_360882].  The DSMC Chairperson determines whether 
action is required and either takes action immediately, convenes a special DSMC session 
(physical  or electronic), or defers the action until a regularly scheduled DSMC meeting.  
 
 
Written reports to:  
(Investigator/study team: Insert names, fax numbers, an addresses for required 
notifications)  
  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
18 UTSW SCCC Data Safety Monitoring Committee Coordinator  
Email: [EMAIL_2258]  
Fax: [ADDRESS_449980] (IRB)  
Submit a Reportable Event via eIRB with a copy of the final sponsor 
report as attached suppor ting documentation  
 
 
Reporting Unanticipated Problems Involving Risks to Subjects or Others 
(UPI[INVESTIGATOR_20865]) to the UTSW HRPP  
 
UTSW reportable event guidance applies to all research conducted by [CONTACT_264025], its affiliates, and investigators, sites, or institutions relying on the UT 
Southwestern IRB. Additional  reporting requirements apply for research relying on a non -
UT Southwestern IRB.  
 
According to UTSW HRPP policy, UPI[INVESTIGATOR_114591], experiences, outcomes, etc. 
that meet ALL three (3)  of the following criteria:  
1. Unexpected in nature, frequency, or sever ity (i.e., generally not expected in a 
subject’s underlying condition or not expected as a risk of the study; therefore, not 
included in the investigator’s brochure, protocol, or informed consent document),AND  
2. Probably or definitely related to participatio n in the research, AND  
3. Suggests that the research places subjects or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was previously 
known or recognized.  Note: According to OHRP, if the adverse event is s erious, it 
would always suggest a greater risk of harm.  
 
For purposes of this policy, UPI[INVESTIGATOR_114592] 
(UADEs) and death or serious injury related to a humanitarian use device (HUD).  
 
UPI[INVESTIGATOR_360883] t o the UTSW HRPP within 5 working days of  
study team awareness.  
 
For research relying on a non -UT Southwestern IRB (external, central, or single IRB) : 
 
Investigators relying on an external IRB who are conducting research on behalf of UT 
Southwestern or its affiliates are responsible for submitting LOCAL  UPI[INVESTIGATOR_264010] [ADDRESS_449981] 
report to their relying IRB according to the relying IRB’s policy. In addition, the external 
IRB’s response s or determinations on these local events must be submitted to the UT 
Southwestern IRB within 10 working days of receipt.  
 
Events NOT meeting UPI[INVESTIGATOR_118278] : 
 
Events that do NOT meet UPI[INVESTIGATOR_114596], evaluated, summarized, 
and submitted to the UTSW HRPP/IRB at continuing review.  
 
For more information on UTSW HRPP/IRB reportable event policy, see 
https://www.utsouthwestern.edu/research/hrpp/quality -assurance/  
7.3 Unblinding Procedures  
Not applicable  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
[ADDRESS_449982] with this study (patent ownership, 
royalties, or financial gain greater than the minimum allowable by [CONTACT_1385], 
etc.) must have the conflict reviewed by [CONTACT_360895] C ommittee and IRB 
according to UTSW Policy  on Conflicts of Interest.  All investigators will follow 
the University conflict of interest policy.  
8.[ADDRESS_449983] (IRB) Approval and Consent  
It is expected that the IRB will have the proper representa tion and function in 
accordance with federally mandated regulations. The IRB must approve the consent 
form and protocol.  
 
In obtaining and documenting informed consent, the investigator should comply 
with the applicable regulatory requirement(s), and shoul d adhere to Good Clinical 
Practice (GCP) and to ethical principles that have their origin in the Declaration of 
Helsinki.  
  
Before recruitment and enrollment onto this study, the subject will be given a full 
explanation of the study and will be given the o pportunity to review the consent 
form. Each consent form must include all the relevant elements currently required 
by [CONTACT_44316]. Once this essential 
information has been provided to the subject and the investigator is assured that the 
subject understands the implications of participating in the study, the subject will 
be asked to give consent to participate in the study by [CONTACT_10001] -approved 
consent form.  
 
Prior to a patient’s participation in the trial, the wri tten informed consent form 
should be signed and personally dated by [CONTACT_360896].  
8.[ADDRESS_449984], call 214 -633-1753 Monday through Friday, 
9:00AM -5:00PM.  
 
Each newly consented subject should be numbered using the schema provided 
above. Upon registration, the registrar will assign the additional 
registration/randomization code according to the numbering schema outlined 
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
20 above, which should then be entered as the patient study id in Velos upon updating 
the status to enrolled.  
 
The numbering schema should clearly identify the site number; the sequential 
number of the subject enrolled as well as the status of the subjects enrolled so that 
the number of subjects consented versus the number of subjects actually enrolled 
may be easil y identified.   
8.4 Data Management and Monitoring/Auditing  
REDCap is the UTSW SCCC institutional choice for the electronic data capture of case 
report forms for SCCC Investigator Initiated Trials. REDCap will be used for electronic case 
report forms in accordance with Simmons Comprehensive Cancer Center requirements, 
as appropriate for the project  
 
Trial monitoring will be conducted according to the study specific monitoring plan. For 
guidance on creating a monitoring plan, refer to the UTSW SCCC IIT Man agement 
Manual.   
   
 
 
The UTSW Simmons Comprehensive Cancer Center (SCCC) Data Safety Monitoring 
Committee (DSMC) is responsible for monitoring data quality and patient safety for all 
UTSW SCCC clinical trials.  As part of that responsibility, the DSMC re views all serious 
adverse events and UPI[INVESTIGATOR_264011] a quarterly basis.  The quality assurance activity for the Clinical Research 
Office provides for periodic auditing of clinical research documents t o ensure data 
integrity and regulatory compliance.  A copy of the DSMC plan is available upon request.  
 
The SCCC DSMC meets quarterly and conducts annual comprehensive reviews of 
ongoing clinical trials, for which it serves as the DSMC of record. The Quali ty Assurance 
Coordinator ( QAC ) works as part of the DSMC to conduct regular audits based on the level 
of risk. Audit findings are reviewed at the next available DSMC meeting.  In this way, 
frequency of DSMC monitoring is dependent upon the level of risk.  Risk level is determined 
by [CONTACT_264031] a number of factors such as the phase of the study; the type 
of investigational agent, device or intervention being studied; and monitoring required to 
ensure the safety of study subjects based on the assoc iated risks of the study. Protocol -
specific DSMC plans must be consistent with these principles.    
 
8.[ADDRESS_449985] requires alternative treatment, the study shall be 
conducted exactly as described in the approved protocol.  
8.5.1  Exceptions (also called sin gle-subject exceptions or single -subject waivers): 
include any departure from IRB -approved research that is not due to an 
emergency  and is:  
 intentional on part of the investigator; or  
 in the investigator’s control; or  
 not intended as a systemic change (e.g., single -subject exceptions to eligibility  
[inclusion/exclusion] criteria)  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
21  Reporting requirement *: Exceptions are non -emergency deviations that require prospective  
IRB approval before being implemented. Call the IRB if your request is 
urgent. If IRB  approval is not obtained beforehand, this constitutes a major 
deviation.  For eligibility waivers, studies which utilize the SCCC -DSMC as the 
DSMC of record must also obtain approval from the DSMC prior to submitting 
to IRB for approval.  
8.5.2  Emergency Deviations: include any departure from IRB -approved research that 
is necessary to:  
 avoid immediate apparent harm, or  
 protect the life or physical well -being of subjects or others  
 Reporting requirement *: Emergency deviations must be promptly 
reported  
to the IRB within 5 working days of occurrence.  
 
8.5.3  Serious Noncompliance (formerly called major deviations  or violations ): 
include any departure from IRB -approved research that : 
 Increase risk of harm to subjects; and/or  
  
adversely affects the rights, safety, or welfare of subjects (any of which may 
also be an unanticipated problem); and/or  
 adversely affects the integrity of the data and research (i.e., substantially 
compromises the integrity, reliability, or validity of t he research)  
 Reporting requirement* : Serious Noncompliance must be promptly 
reported tothe IRB within 5 working days of discovery. . 
 
8.5.4  Continuing Noncompliance: includes a pattern of repeated    
noncompliance (in  or more protocols simultaneously, or over a period of time) 
which continues after  initial discovery, including inadequate efforts to take or 
implement corrective or preventive action within a reasonable time frame.  
 Reporting requirement* : Continuing Noncompliance must be promptly 
reported to the IRB within 5 working days of discovery.  
 
8.5.5  Noncompliance (that is neither serious nor continuing; formerly called 
minor deviations) any departure from IRB-approved research that:  
 Does not meet the definition of serious noncompliance or continuing 
noncompliance  
 Reporting requirement*: Noncompliance that is neither serious nor continuing  
should be tracked and summarized the next IRB continuing review, o r the notice 
of study closure - whichever comes first..  
 
*Reporting Requirements reflect UTSW HRPP/IRB guidelines; participating sites should follow 
the reporting guidelines for their IRB of record  
 
8.6 Amendments to the Protocol  
Should amendments to the protocol be required, the amendments will be originated 
and documented by [CONTACT_079].  A summary of changes document 
outlining proposed changes as well as rationale for changes, when appropriate, is 
highly recommend ed.  When an amendment to the protocol substantially alters the 
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
[ADDRESS_449986] Retention  
Study documentation includes all Case Report Forms, data correction forms or 
queries, source documents, Sponsor -Investigator correspondence, monitoring 
logs/letters, and regulatory documents (e.g., protocol a nd amendments, IRB 
correspondence and approval, signed patient consent forms).  
 
Source documents include all recordings of observations or notations of clinical 
activities and all reports and records necessary for the evaluation and reconstruction 
of the clinical research study.  
 
Government agency regulations and directives require that the study investigator 
retain all study documentation pertaining to the conduct of a clinical trial. In the 
case of a study with a drug seeking regulatory approval and mark eting, these 
documents shall be retained for at least two years after the last approval of 
marketing application in an International Conference on Harmonization (ICH) 
region. In all other cases, study documents should be kept on file until three years 
after the completion and final study report of this investigational study.  
8.[ADDRESS_449987] of the clinical trial at the 
site in accordance with Title 21 of the Code of Federal Regulations a nd/or the 
Declaration of Helsinki. The Principal Investigator [INVESTIGATOR_252948]. The Principal Investigator [INVESTIGATOR_252949], including sub -investigators and other study st aff 
members, adhere to the study protocol and all FDA/GCP/NCI regulations and 
guidelines regarding clinical trials both during and after study completion.  
 
The Principal Investigator [INVESTIGATOR_360884]. 
Periodically, monitoring visits may be conducted and the Principal Investigator [INVESTIGATOR_360885]/her original records to permit verification of proper entry of 
data. At the completion of the study, all case report forms will be reviewed by [CONTACT_1268] [INVESTIGATOR_44302]/her final signature [CONTACT_246137].  
9.0 REFERENCES  
 
1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer stat istics, 2016.  CA Cancer J Clin, 2016. 
66(1): p. 7 -30. 
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
23 2. Wu, J., et al., Early -Stage Non -Small Cell Lung Cancer: Quantitative Imaging 
Characteristics of 18F Fluorodeoxyglucose PET/CT Allow Prediction of Distant 
Metastasis.  Radiology, 2016: p. 151829.  
3. Timmerman, R., et al., Stereotactic Body Radiation Therapy for Inoperable Early Stage 
Lung Cancer.  Jama -Journal of the American Medical Association, 2010. 303(11): p. 
1070 -1076.  
4. Chang, E.L., et al., Phase I/II study of stereotactic body radiotherapy for s pi[INVESTIGATOR_360886].  Journal of Neurosurgery: Spi[INVESTIGATOR_050], 2007. 7(2): p. 151 -
160. 
5. Huang, M., et al., Brain tumor segmentation based on local independent projection -based 
classification.  IEEE Trans Biomed Eng, 2014. 61(10): p. 2633 -45. 
6. Chi, A., et al., Systemic review of the patterns of failure following stereotactic body 
radiation therapy in early -stage non -small -cell lung cancer: clinical implications.  
Radiother Oncol, 2010. 94(1): p. 1 -11. 
7. Matsuo, Y., et al., Dose --volume metri cs associated with radiation pneumonitis after 
stereotactic body radiation therapy for lung cancer.  Int J Radiat Oncol Biol Phys 2012. 
83: p. e545 -549  
8. Timmerman, R., et al., Excessive toxicity when treating central tumors in a phase II study 
of stereot actic body radiation therapy for medically inoperable early -stage lung cancer.  J 
Clin Oncol, 2006. 24(30): p. 4833 -9. 
9. Jiang, S.B., Radiotherapy of mobile tumors.  Semin Radiat Oncol, 2006. 16(4): p. 239 -48. 
10. Keall, P.J., et al., The management of resp iratory motion in radiation oncology report of 
AAPM Task Group 76.  Med Phys, 2006. 33(10): p. 3874 -900. 
11. Meyer, J.J., et al., A Phase I Dose -Escalation Trial of Single -Fraction Stereotactic 
Radiation Therapy for Liver Metastases.  Ann Surg Oncol, 2016. 23(1): p. 218 -24. 
12. Hanley, J., et al., Deep inspi[INVESTIGATOR_212746] -hold technique for lung tumors: the potential 
value of target immobilization and reduced lung density in dose escalation.  Int J Radiat 
Oncol Biol Phys, 1999. 45(3): p. [ADDRESS_449988] wall using active breathing control: a reproducibility 
study with breast cancer patients.  Int J Radiat Oncol Biol Phys, 2003. 57(4): p. [ADDRESS_449989] cancer patients.  Int J Radiat Oncol Biol Phys, 2001. 
49(1): p. 199 -204. 
15. Plathow, C., et al., Influence of different breathing maneuvers on i nternal and external 
organ motion: use of fiducial markers in dynamic MRI.  Int J Radiat Oncol Biol Phys, 
2005. 62(1): p. [ADDRESS_449990] cancer using external beam radiation therapy.  International Journal of 
Radiation Oncology*Biology*Physics, 2003. 56(3): p. [ADDRESS_449991] radiotherapy with an optical tracking system.  Medical Physics, 2015. 42(1): p. 
134-143. 
18. Parkes, M.J., et al., Assessing and ensuring patient safety during breath -holding for 
radiotherapy.  Br J Radiol, 2014 . 87(1043): p. 20140454.  
STU 022017 -075 
________________________________________________________________________  
STU022017 -075, P arsons, FormA -ResearchProtocol, Mod_17, 06 -15-21 (2)   
24 19. Parkes, M.J., et al., Safely prolonging single breath -holds to >5 min in patients with 
cancer; feasibility and applications for radiotherapy.  Br J Radiol, 2016. 89(1063): p. 
20160194.  
 